Adult Dosing
Diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature
- Inject 5 ml of 10% solution or 2 ml of 25% solution (500 mg) over 5-10 seconds is normally recommended into the antecubital vein, after taking precautions to avoid extravasation
- Usual dose: 500 mg IV
Note: Consider reduction in dose in cases when a highly sensitive imaging system such as scanning laser ophthalmoscope is used
Pediatric Dosing
Diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature
- Calculate dose on the basis of 35 mg/10 pounds of body weight (7.7 mg/kg body weight). Use the 10% solution
- Inject calculated dose at a rate of approx. 1 ml per second of 10% solution
- Max dose of 500 mg IV
[Outline]
See Supplemental Patient Information
- For IV use only
- Take care to avoid extravasation during injection as the high pH of fluorescein solution leads to severe local tissue damage. Complications such as sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median curve in the antecubital area have occurred
- Severe pain in the arm for up to several hours has occurred following complications resulting from extravasation. Discontinue therapy following significant extravasation and undertake conservative measures to treat damaged tissue and to relieve pain
- Rare occasions of death due to anaphylaxis have occurred
- Keep ready emergency tray in the event of possible reaction
- On suspicion of potential allergy perform an intradermal skin test prior to intravenous administration
Caution: Use cautiously in:
Supplemental Patient Information
- Inform patients that skin will attain a temporary yellowish discoloration and urine will attain a bright yellow color. Also inform patients that discoloration of the skin and urine will fade in 6-12 hrs and 24-36 hrs respectively
Pregnancy Category:C
Breastfeeding: IV use in a nursing mother results in higher levels in infant. Unlikely that these higher levels are problematic for most infants, but avoid exposure to intense light, such as phototherapy, for a few days after the maternal dose. Fluorescein is not expected to cause any adverse effects in breastfed infants. Place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue for diminishing the amount of drug that reaches the breastmilk after using eye drops, This data is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 February 2011). Manufacturer advises caution.
US Trade Name(s)
- AK-Fluor 10%
- AK-Fluor 25%
- Fluorescite
US Availability
AK-Fluor 10%
AK-Fluor 25%
Fluorescite
- INJ: 100 mg/mL (5 mL vial)
Canadian Trade Name(s)
- AK-Fluor 10%
- AK-Fluor 25%
- Diofluor 10%
- Diofluor 25%
- Fluorescite
Canadian Availability
AK-Fluor 10%
AK-Fluor 25%
Diofluor 10%, Fluorescite
Diofluor 25%
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
fluorescein (generic)
- INJ: 100 mg/mL (5 mL amp)
Fluorescite
Retinofluor
- INJ: 100 mg/mL (5,10 mL vial)
- INJ: 250 mg/mL (5 mL vial)
[Outline]